<ul>
<li>Genmab revenue climbed 25% to $896 million for the three months ended March 31, 2026, while operating profit slipped to $180 million from $188 million.     *      Royalty revenue increased 26% to $742 million, driven by higher net sales of DARZALEX and Kesimpta.     *      Cost of product sales rose 55% to $65 million, mainly on higher profit-sharing amounts payable to AbbVie related to EPKINLY sales.     *      Operating expenses excluding acquisition and integration charges increased 25% to $606 million, reflecting pipeline expansion and continued investment in commercialization ahead of projected launches of Rina-S and petosemtamab.     *      FDA approved an sBLA removing the recommendation for 24-hour hospitalization for patients with third line relapsed/refractory DLBCL; Genmab maintained 2026 financial guidance. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605071101PRIMZONEFULLFEED1001180659) on May 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</li>
</ul>

ABBV

GMAB

<p>Genmab reported a 25% increase in revenue to $896 million for Q1 FY26, while operating profit decreased to $180 million from $188 million. Royalty revenue rose 26% to $742 million, driven by higher sales of DARZALEX and Kesimpta. Costs of product sales increased by 55% to $65 million, primarily due to higher profit-sharing with AbbVie. Operating expenses, excluding acquisition charges, grew 25% to $606 million, reflecting investments in pipeline expansion. The FDA approved an sBLA for DLBCL, and Genmab maintained its 2026 financial guidance.</p>

PUBT

Abbvie

Genmab A/S

Health Care Select Sector SPDR

VG Health

iShares US Pharma

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

VanEck Biotech ETF

SPDR S&P Biotech

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Genmab Q1 FY26 operating profit slips to $180 million; revenue climbs 25% to $896 million